Corvus Pharmaceuticals (CRVS) Current Assets (2015 - 2026)

Corvus Pharmaceuticals' Current Assets history runs 12 years deep, the most recent figure standing at $239.9 million for Q1 2026.

• On a quarterly basis, Current Assets rose 427.46% year-over-year to $239.9 million in Q1 2026; TTM through Mar 2026 was $239.9 million, a 427.46% increase from a year earlier, with the FY2025 full-year figure at $58.2 million, up 7.0% from the prior year.
• Current Assets rose to $239.9 million in Q1 2026 per CRVS's latest filing, from $58.2 million in the prior quarter.
• Across five years, Current Assets topped out at $239.9 million in Q1 2026 and bottomed at $22.9 million in Q1 2024.
• The 5-year median for Current Assets is $48.3 million (2024), against an average of $59.3 million.
• Across the five-year window, Current Assets slumped 44.77% in 2023 and jumped 427.46% in 2026, its largest moves.
• Year by year, Current Assets stood at $43.7 million in 2022, then plunged by 35.97% to $28.0 million in 2023, then soared by 94.62% to $54.4 million in 2024, then grew by 7.0% to $58.2 million in 2025, then jumped by 312.18% to $239.9 million in 2026.
• Per Business Quant, the three latest CRVS Current Assets figures stand at $239.9 million (Q1 2026), $58.2 million (Q4 2025), and $66.9 million (Q3 2025).